Bharat Biotech Unveils New Brand Identity
Vaccine maker Bharat Biotech has unveiled its new corporate logo and vision for the future. With its new logo and tag line ‘Lead Innovation’, the Hyderabad-based company is underlining its focus for developing new made-in-India molecules to prevent neglected diseases that affect a large populace in the developing world.
This new logo launch coincides with Bharat Biotech’s 20 years of operations. To mark the occasion, it had committed to contribute Rs. 1-crore worth of vaccines to the Telangana government for its public health immunisation. “This year has been a double treat for the Bharat Biotech family, with our two pathbreaking vaccines Typbar TCV and Rotavac, getting global recognition and endorsement from the World Health Organisation (WHO). These developments reinforce our foundation for the next stage of growth,” Dr. Krishna Ella, Chairman and Managing Director, said in a release.
Looking for chemical products? Let suppliers reach out to you!
2026-07-14
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The Dangers Of Vaccines That Commenly Used
-
An Insight Into The Vaccine Causing Blood Clots
-
Overview Of The Top 5 Vaccine Companies In China
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
Analysis of the biggest producer of vaccines on coronavirus in China
-
6 Drugs Sold For Nearly $120 Billion
-
Two inactivated vaccines against COVID-19 start clinical trials
-
Bill Gates is funding factories for 7 potential coronavirus vaccines
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Recommend Reading
-
NHU and Sinopec Advance Liquid Methionine Project
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
China’s EVA Market Has Entered a Downward Trend Since May
-
Negative Factors Persist, Palm Oil Market Weakens and Declines
-
This Week's PVC Prices Narrowly Declined in China
-
This Week, China's Titanium Dioxide Market Trended Upward (9.1-9.5)
-
Manufacturers Continue to Push for Price Increases, Acrylonitrile Market Rises Slightly